Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway

1 Apr 2019

Abstract excerpt

Radiation therapy is often combined with androgen deprivation therapy in the treatment of aggressive localized prostate cancer. However, castration-resistant disease may not respond to testosterone deprivation approaches. Enzalutamide is a second-generation anti-androgen with high affinity and activity that is used for the treatment of metastatic disease. Although radiosensitization mechanisms are known to be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30933998
DOI: 10.1371/journal.pone.0214670

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathwayPMID 30933998Read ↗

Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived XenograftsSemantic proximity Read ↗

Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistanceSemantic proximity Read ↗

Targeting androgen receptor-independent pathways in therapy-resistant prostate cancerSemantic proximity Read ↗

ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.Semantic proximity Read ↗

Sensitization of prostate cancer to radiation therapy: Molecules and pathways to target.Semantic proximity Read ↗

Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice VariantsSemantic proximity Read ↗

The interconnection between androgen receptor and DNA damage response pathways in prostate cancerSemantic proximity Read ↗

Androgen receptor contributes to radioresistance through DNA repair and autophagy in AR-positive prostate cancer cellsSemantic proximity Read ↗

Inhibition of telomerase potentiates enzalutamide efficiency of androgen-sensitive human prostate cancer cells.Semantic proximity Read ↗

Use of PARP inhibitors in prostate cancer: from specific to broader application.Semantic proximity Read ↗

Uncovering the Secrets of Prostate Cancer’s Radiotherapy Resistance: Advances in Mechanism ResearchSemantic proximity Read ↗

Epigenetic mechanisms underlying prostate cancer radioresistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.